Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

Clinical trial NCT02428660 · COMPLETED

Trial details

NCT number: NCT02428660
Sponsor: Genelex Corporation
Status: COMPLETED
Phase: Not Applicable
Study type: INTERVENTIONAL

Cytochrome P450 CYP2D6 Enzyme Deficiency Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant Cytochrome P450 CYP2C9 Enzyme Deficiency Cytochrome P450 CYP2C19 Enzyme Deficiency Drug Metabolism, Poor, CYP2D6-RELATED Drug Metabolism, Poor, CYP2C19-RELATED CYP2D6 Polymorphism

Start date: 2015-02-01
Primary completion: 2017-02-01
Enrollment: 341

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.